KBC Group
SRPT icon

KBC Group’s Sarepta Therapeutics SRPT Stock Holding History

KBC Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57K Hold
3,152
– – ﹤0.01% 1669
2026
Q1 		$69K Hold
3,152
– – ﹤0.01% 1521
2025
Q4 		$68K Hold
3,152
– – ﹤0.01% 1512
2025
Q3 		$61K Hold
3,152
– – ﹤0.01% 1568
2025
Q2 		$54K Sell
3,152
-543
-15% -$23.2K ﹤0.01% 1576
2025
Q1 		$236K Sell
3,695
-5
-0.1% -$526 ﹤0.01% 982
2024
Q4 		$450K Buy
3,700
+1,361
+58% +$167K ﹤0.01% 831
2024
Q3 		$292K Buy
2,339
+238
+11% +$32.9K ﹤0.01% 802
2024
Q2 		$332K Buy
2,101
+173
+9% +$22.2K ﹤0.01% 752
2024
Q1 		$250K Buy
1,928
+448
+30% +$54.9K ﹤0.01% 806
2023
Q4 		$143K Hold
1,480
– – ﹤0.01% 921
2023
Q3 		$179K Buy
+1,480
New +$167K ﹤0.01% 852
2021
Q4 		– Sell
-555
Closed -$51K – 1334
2021
Q3 		$51K Sell
555
-6,347
-92% -$489K ﹤0.01% 1238
2021
Q2 		$537K Sell
6,902
-37
-0.5% -$2.81K ﹤0.01% 860
2021
Q1 		$517K Hold
6,939
– – ﹤0.01% 863
2020
Q4 		$1.18M Hold
6,939
– – 0.01% 729
2020
Q3 		$974K Sell
6,939
-3,096
-31% -$471K 0.01% 717
2020
Q2 		$1.61M Buy
10,035
+2,050
+26% +$279K 0.01% 607
2020
Q1 		$781K Buy
7,985
+2,544
+47% +$291K 0.01% 752
2019
Q4 		$702K Buy
5,441
+3,341
+159% +$337K ﹤0.01% 1012
2019
Q3 		$158K Buy
2,100
+1,485
+241% +$175K ﹤0.01% 1288
2019
Q2 		$93K Hold
615
– – ﹤0.01% 1310
2019
Q1 		$73K Buy
+615
New +$79.1K ﹤0.01% 1293

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

KBC Group's SRPT Position: Q2 2026 in Review

KBC Group held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 3,152 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

KBC Group first reported a position in SRPT in Q1 2019 and has held it in 23 quarters since. The position peaked at $1.61M in Q2 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • KBC Group held 3,152 shares of Sarepta Therapeutics worth $57K as of Q2 2026.
  • KBC Group left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1669 holding.
  • KBC Group first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 23 quarters since.
  • KBC Group's Sarepta Therapeutics position peaked at $1.61M in Q2 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.